close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

175.66 +0.46 (+0.26%)
Streaming Delayed Price Updated: 9:30 AM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients ↗
 
Via Benzinga
News headline image
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
News headline image
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting ↗
 
Via Benzinga
News headline image
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade ↗
 
Via Benzinga
News headline image
AstraZeneca's Imfinzi Combo Scores FDA Approval For Liver Cancer ↗
 
Via Benzinga
News headline image
AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA ↗
 
Via Benzinga
News headline image
AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline ↗
 
Via Benzinga
News headline image
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says ↗
 
Via Benzinga
News headline image
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings ↗
 
Via Benzinga
News headline image
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs ↗
 
Via Benzinga
News headline image
AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting ↗
 
Via Benzinga
News headline image
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza ↗
 
Via Benzinga
News headline image
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients ↗
 
Via Benzinga
News headline image
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials ↗
 
Via Benzinga
News headline image
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer ↗
 
Via Benzinga
News headline image
AstraZeneca Bets On UK Listed Firm For Lung Diseases ↗
 
Via Benzinga
News headline image
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗
 
Via Benzinga
News headline image
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs ↗
 
Via Benzinga
News headline image
FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer ↗
 
Via Benzinga
News headline image
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength ↗
 
Via Benzinga
News headline image
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids ↗
 
Via Benzinga
News headline image
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants ↗
 
Via Benzinga
News headline image
European Regulator Grants Complete Approval To AstraZeneca's COVID-19 Vaccine ↗
 
Via Benzinga
News headline image
AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord ↗
 
Via Benzinga
News headline image
AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings ↗
 
Via Benzinga
News headline image
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation ↗
 
Via Benzinga
News headline image
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery ↗
 
Via Benzinga
News headline image
AstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial ↗
AstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection. 
Via Benzinga
News headline image
Why Are LogicBio Therapeutics Shares Skyrocketing Today? ↗
 
Via Benzinga
News headline image
How To Invest In UK Market Turmoil ↗
With investors speculating about what steps the central bank might take, it’s clear that the UK’s turbulence is far from over. So, let’s take a look at the market winners and losers that are likely to... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today